% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Amitay:153167,
author = {E. Amitay$^*$ and P. R. Carr$^*$ and L. Jansen$^*$ and E.
Alwers$^*$ and W. Roth and E. Herpel and M. Kloor and H.
Bläker and J. Chang-Claude$^*$ and H. Brenner$^*$ and M.
Hoffmeister$^*$},
title = {{P}ostmenopausal hormone replacement therapy and colorectal
cancer risk by molecular subtypes and pathways.},
journal = {International journal of cancer},
volume = {147},
number = {4},
issn = {1097-0215},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2020-00220},
pages = {1018-1026},
year = {2020},
note = {2020 Aug 15;147(4):1018-1026#EA:C070#LA:C070#},
abstract = {Postmenopausal hormone replacement therapy (HRT) was found
to be associated with lower risk of colorectal cancer (CRC).
However, little is known regarding associations with
molecular subtypes of CRC. The current study includes female
participants of a large German population-based case-control
study (922 CRC cases and 1,183 controls). Tumor tissue
samples were analyzed for microsatellite instability (MSI),
CpG island methylator phenotype (CIMP), BRAF and KRAS
mutation status. Multivariable logistic regression models
were used to assess the association of HRT use with
molecular subtypes and pathways. Postmenopausal HRT use was
overall associated with reduced risk of CRC (adjusted
odds-ratio (aOR) 0.62, $95\%$ confidence interval (CI)
0.50-0.76) and no major differences were observed for
molecular subtypes or for tumor marker combinations
representing molecular pathways. When stratified by median
age (≤/>71 years) potentially stronger risk reductions
were observed in the older group for subtypes showing MSI
(OR = 0.36, $95\%CI$ 0.17-0.76), BRAF mutation
(OR = 0.40, $95\%CI$ 0.30-0.83) and CIMP-high
(OR = 0.40, $95\%CI$ 0.21-0.73) and for CRC suggestive of
the sessile serrated pathway (OR = 0.45, $95\%CI$
0.20-1.01). In conclusion, postmenopausal use of HRT was
similarly associated with risk reduction of major molecular
tumor subtypes and pathways of CRC. Potentially stronger
risk reductions with CRC subtypes diagnosed at higher ages
require confirmation and clarification from other studies.
The current study extends the limited understanding of the
mechanisms of HRT in CRC prevention. This article is
protected by copyright. All rights reserved.},
cin = {C070 / C120 / HD01 / C020},
ddc = {610},
cid = {I:(DE-He78)C070-20160331 / I:(DE-He78)C120-20160331 /
I:(DE-He78)HD01-20160331 / I:(DE-He78)C020-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31943160},
doi = {10.1002/ijc.32868},
url = {https://inrepo02.dkfz.de/record/153167},
}